Slide 1 of 1 
Equine CXCL7 Recombinant Protein
- Catalog Number:
- RP1869E
- Availability:
- In stock
- Application:
- Cell Culture, ELISA Standard, ELISpot Control, Western Blot Control
- 100% Homology:
- Equus caballus (horse), Equus przewalskii (Przewalski's horse)
- Equine CXCL7 (NAP-2, Neutrophil-Activating Peptide 2) (catalog RP1869E) is a yeast-derived chemokine supplied lyophilized without carrier protein in 10% trehalose; it has no affinity tags and is naturally endotoxin-free, and should be reconstituted in sterile PBS that contains at least 0.1% carrier protein. The protein is ~11.2 kDa, 104 amino acids long (full sequence provided), and >98% pure by SDS-PAGE, with 100% amino-acid homology to horse and Przewalski's horse. Store at -20°C (stable up to twelve months from date of receipt; working aliquots with carrier protein stable ~3 months) and avoid repeated freeze/thaw cycles. Product origin is the USA. It is commonly used to study CXCL7/NAP-2 signaling and immune responses (including activation and recruitment of neutrophils during inflammatory processes); typical experimental uses include cell-culture stimulation and migration assays, chemotaxis and signaling studies, ELISA and neutralization assays, flow-cytometry and Western blot controls, and antibody generation/validation. Kingfisher Biotech products are supplied for research applications and are not intended for medicinal, diagnostic, or therapeutic use.
| Amino Acid Sequence | TITIGEISTL AKSVDDELYA ELRCLCVKTT SGIHPRIIQT LQVIRAGPHC SKVEVIATLK NGKEICLDPG AVRIKNIVQK ILESDGSAAS SVHILSNLSD SQEE (104) |
| Endotoxin | Naturally endotoxin-free |
| Storage Conditions | -20°C |
| Molecular Weight | 11.2 kDa |
| Purity | >98% as visualized by SDS-PAGE analysis. |
| Country Of Origin | USA |
- Equine CXCL7 (C-X-C motif chemokine ligand 7), also known as NAP-2 (neutrophil-activating peptide 2) or PPBP (pro-platelet basic protein), is a platelet-derived chemokine belonging to the ELR⁺ CXC chemokine family, which includes CXCL1, CXCL2, CXCL3, and CXCL5 that regulate neutrophil recruitment during inflammatory responses. In horses (Equus caballus), CXCL7 is produced primarily by platelets and megakaryocytes and is released during platelet activation following vascular injury, inflammation, or infection. CXCL7 signals mainly through the chemokine receptor CXCR2, expressed on neutrophils and other innate immune cells, promoting neutrophil chemotaxis, activation, and migration to sites of tissue damage or infection. In equine health, CXCL7 contributes to the interaction between hemostasis and immune responses, particularly during inflammatory conditions affecting the vascular system, musculoskeletal tissues, and respiratory tract, where platelet activation and neutrophil recruitment support host defense and tissue repair. Horses are also used as comparative animal models for musculoskeletal and inflammatory diseases, and platelet-derived chemokines such as CXCL7 have been examined in equine models of tendon and ligament injury, where platelet-rich plasma (PRP) therapies release platelet chemokines that influence inflammation, leukocyte recruitment, and tissue regeneration, providing insight into platelet-mediated healing mechanisms relevant to both veterinary and human medicine.
Please choose a size to see price
RELATED MEDIA
